These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 26302499)

  • 1. Is Mean Platelet Volume Actually Significantly Higher in Patients With Nonalcoholic Fatty Liver Disease?
    Beyan C; Beyan E
    J Clin Gastroenterol; 2015; 49(10):888. PubMed ID: 26302499
    [No Abstract]   [Full Text] [Related]  

  • 2. Mean platelet volume in patients with non-alcoholic fatty liver disease: is mean platelet volume ready as a surrogate marker?
    Kocabay G; Karabay CY; Kalayci A; Colak Y
    Clin Chem Lab Med; 2014 Nov; 52(11):e249-52. PubMed ID: 24850543
    [No Abstract]   [Full Text] [Related]  

  • 3. The relationship between insulin resistance, metabolic syndrome and nonalcoholic fatty liver disease in non-obese non-diabetic Turkish individuals: A pilot study.
    Erkan G; Sayın I; Polat FB; Çorakçı A; Ataç GK; Değertekin H
    Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():63-8. PubMed ID: 25910371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter: role of mean platelet volume levels in the prediction of major acute cardiovascular events in patients with non-alcoholic fatty liver disease.
    Liu YY; Zhang WY; Zeng DX
    Aliment Pharmacol Ther; 2019 Nov; 50(10):1139. PubMed ID: 31657472
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial: importance of an elevated mean platelet volume for prediction of major adverse cardiovascular events in non-alcoholic fatty liver disease.
    Targher G; Lippi G
    Aliment Pharmacol Ther; 2019 Apr; 49(8):1092-1093. PubMed ID: 30920047
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter: role of mean platelet volume levels in the prediction of major acute cardiovascular events in patients with non-alcoholic fatty liver disease-authors' reply.
    Mullish BH; Forlano R; Abeles RD; Thursz MR; Manousou P
    Aliment Pharmacol Ther; 2019 Nov; 50(10):1140-1141. PubMed ID: 31657474
    [No Abstract]   [Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease and polycystic ovary syndrome.
    Polyzos SA; Goulis DG; Kountouras J
    Ann Hepatol; 2015; 14(6):941-3. PubMed ID: 26436371
    [No Abstract]   [Full Text] [Related]  

  • 8. [Autophagy and nonalcoholic fatty liver disease].
    Li XQ; Wang W; Jia YH; Zhao CY
    Zhonghua Gan Zang Bing Za Zhi; 2016 Aug; 24(8):632-635. PubMed ID: 27788715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to 'Effect of metabolic components on incident type 2 diabetes mellitus in nonalcoholic fatty liver disease subjects'.
    Fukuda T; Hamaguchi M; Fukui M
    Liver Int; 2016 Mar; 36(3):462. PubMed ID: 26442842
    [No Abstract]   [Full Text] [Related]  

  • 10. Mean platelet volume for differentiating non-alcoholic fatty liver disease from non-alcoholic steatohepatitis: Is it ready for prime time?
    Madan K; Garg P
    Indian J Gastroenterol; 2023 Apr; 42(2):156-157. PubMed ID: 37213042
    [No Abstract]   [Full Text] [Related]  

  • 11. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
    Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
    Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin sensitizers in nonalcoholic steatohepatitis.
    Harrison SA; Schenker S; Cusi K
    Hepatology; 2011 Apr; 53(4):1404-5; author reply 1405. PubMed ID: 21480350
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial: importance of an elevated mean platelet volume for prediction of major adverse cardiovascular events in non-alcoholic fatty liver disease - authors' reply.
    Mullish BH; Forlano R; Abeles RD; Thursz MR; Manousou P
    Aliment Pharmacol Ther; 2019 Apr; 49(8):1093-1094. PubMed ID: 30920045
    [No Abstract]   [Full Text] [Related]  

  • 14. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome.
    Dietrich P; Hellerbrand C
    Best Pract Res Clin Gastroenterol; 2014 Aug; 28(4):637-53. PubMed ID: 25194181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical importance of the nonalcoholic fatty liver disease: a review.
    Chumak AA; Ovsyannikova LM; Sarkisova EA; Gasanova EV
    Probl Radiac Med Radiobiol; 2013; (18):277-88. PubMed ID: 25191732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Ceramides.
    Samuel VT; Shulman GI
    N Engl J Med; 2019 Nov; 381(19):1866-1869. PubMed ID: 31693811
    [No Abstract]   [Full Text] [Related]  

  • 17. Is nonalcoholic fatty liver disease in children the same disease as in adults?
    Hsu E; Murray K
    Clin Liver Dis; 2012 Aug; 16(3):587-98. PubMed ID: 22824482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance and hypothyroidism: a complex relationship in non-alcoholic fatty liver disease.
    Misra S; Singh B
    J Indian Med Assoc; 2013 May; 111(5):324-6, 329. PubMed ID: 24765691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of non-alcoholic fatty liver disease.
    Yki-Järvinen H; Luukkonen PK
    Liver Int; 2015 Dec; 35(12):2498-500. PubMed ID: 26386359
    [No Abstract]   [Full Text] [Related]  

  • 20. MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator.
    Zhuge B; Li G
    Biochem Biophys Res Commun; 2017 Dec; 494(3-4):687-692. PubMed ID: 29107687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.